MX2015013263A - Conjugados de hemoglobina oxido de polialquileno valerato. - Google Patents
Conjugados de hemoglobina oxido de polialquileno valerato.Info
- Publication number
- MX2015013263A MX2015013263A MX2015013263A MX2015013263A MX2015013263A MX 2015013263 A MX2015013263 A MX 2015013263A MX 2015013263 A MX2015013263 A MX 2015013263A MX 2015013263 A MX2015013263 A MX 2015013263A MX 2015013263 A MX2015013263 A MX 2015013263A
- Authority
- MX
- Mexico
- Prior art keywords
- valerate
- polyalkylene oxide
- hemoglobin conjugates
- hemoglobin
- polyethylene glycol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/41—Porphyrin- or corrin-ring-containing peptides
- A61K38/42—Haemoglobins; Myoglobins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/795—Porphyrin- or corrin-ring-containing peptides
- C07K14/805—Haemoglobins; Myoglobins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
Abstract
La presente invención se refiere generalmente a hemoglobinas conjugadas de polietilenglicol (PEG) realizadas mediante conjugación de polietilenglicol activado por succinimidil-valerato a aminas primarios y valinas de extremo N terminal de la hemoglobina.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361801016P | 2013-03-15 | 2013-03-15 | |
PCT/US2014/030569 WO2014145755A1 (en) | 2013-03-15 | 2014-03-17 | Polyalkylene oxide valerate hemoglobin conjugates |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2015013263A true MX2015013263A (es) | 2015-12-11 |
Family
ID=51538084
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015013263A MX2015013263A (es) | 2013-03-15 | 2014-03-17 | Conjugados de hemoglobina oxido de polialquileno valerato. |
Country Status (11)
Country | Link |
---|---|
US (1) | US10821158B2 (es) |
EP (1) | EP2968597B1 (es) |
JP (1) | JP6657070B2 (es) |
KR (1) | KR102238718B1 (es) |
CN (1) | CN105188761B (es) |
AU (1) | AU2014232540B2 (es) |
BR (1) | BR112015023233A8 (es) |
CA (1) | CA2906878C (es) |
HK (1) | HK1219053A1 (es) |
MX (1) | MX2015013263A (es) |
WO (1) | WO2014145755A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10506829B2 (en) | 2016-02-26 | 2019-12-17 | Freelander Innovations USA, LLC | System and method for a vaporizer |
AU2018304174A1 (en) | 2017-07-18 | 2020-02-06 | VirTech Bio, Inc. | Blood substitutes comprising hemoglobin and methods of making |
GB201721503D0 (en) | 2017-12-20 | 2018-01-31 | Univ Essex | Modified globin proteins |
CA3149234A1 (en) * | 2019-08-29 | 2021-03-04 | Kwok Chu Butt | Thiosuccinyl-crosslinked hemoglobin analogs and methods of use and preparation thereof |
CN114786705B (zh) * | 2019-12-06 | 2023-05-12 | 环喜有限公司 | 治疗炎症性肠病的方法 |
US11857605B2 (en) | 2021-03-01 | 2024-01-02 | Billion King International Limited | Thiosuccinyl-crosslinked hemoglobin conjugates and methods of use and preparation thereof |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4529719A (en) | 1983-05-04 | 1985-07-16 | Tye Ross W | Modified crosslinked stroma-free tetrameric hemoglobin |
DE3675588D1 (de) * | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
CA1312009C (en) | 1986-11-10 | 1992-12-29 | Carl W. Rausch | Extra pure semi-synthetic blood substitute |
GB8710598D0 (en) | 1987-05-05 | 1987-06-10 | Star Medical Diagnostics Ltd | Hemoglobin based blood substitute |
US5650388A (en) | 1989-11-22 | 1997-07-22 | Enzon, Inc. | Fractionated polyalkylene oxide-conjugated hemoglobin solutions |
US5234903A (en) | 1989-11-22 | 1993-08-10 | Enzon, Inc. | Chemically modified hemoglobin as an effective, stable non-immunogenic red blood cell substitute |
US5250665A (en) | 1991-05-31 | 1993-10-05 | The University Of Toronto Innovations Foundation | Specifically β-β cross-linked hemoglobins and method of preparation |
US6054427A (en) * | 1997-02-28 | 2000-04-25 | The Regents Of The University Of California | Methods and compositions for optimization of oxygen transport by cell-free systems |
KR100316154B1 (ko) | 1999-03-26 | 2001-12-12 | 노광 | 폴리에틸렌글리콜-헤모글로빈 결합체 |
DE10031744A1 (de) * | 2000-06-29 | 2002-01-17 | Sanguibio Tech Ag | Mit Blutplasma verträgliche, vernetzte und mit Polyalkylenoxiden konjugierte Säugetierhämoglobine als künstliche medizinische Sauerstoffträger, ihre Herstellung und ihre Verwendung |
DE10031740A1 (de) | 2000-06-29 | 2002-02-14 | Sanguibio Tech Ag | Künstliche Sauerstoffträger aus vernetztem modifizierten Human- oder Schweinehämoglobin mit verbesserten Eigenschaften, Verfahren zu ihrer technisch einfachen Herstellung aus gereinigtem Material in hohen Ausbeuten, sowie deren Verwendung |
US20030153491A1 (en) | 2002-01-11 | 2003-08-14 | Winslow Robert M. | Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin |
DE10220992A1 (de) | 2002-05-11 | 2003-12-04 | Sanguibiotech Ag | Verwendung eines oder mehrerer Sauerstoffträger, ausgewählt aus Hämoglobin, Myoglobin und Derivaten hiervon zur Behandlung einer Organfunktionsstörung infolge eines akuten Versorgungsmangels und zur Behandlung/Vermeidung einer Gewebeschädigung infolge einer solchen Störung |
WO2004012773A1 (en) | 2002-07-24 | 2004-02-12 | F. Hoffmann-La Roche Ag | Polyalkylene glycol acid additives |
US20040072729A1 (en) | 2002-10-10 | 2004-04-15 | Sunbio Inc. | High oxygen affinity PEG-hemoglobin as treatment for brain stroke |
AU2003299700B2 (en) * | 2002-12-23 | 2009-03-26 | Albert Einstein College Of Medicine Of Yeshiva University | Modified hemoglobin and methods of making same |
KR100512483B1 (ko) | 2003-05-07 | 2005-09-05 | 선바이오(주) | 신규한 폴리에틸렌글리콜-말레이미드 유도체의 합성방법 |
DE10352692A1 (de) | 2003-11-12 | 2005-06-23 | Sanguibiotech Gmbh | Verwendung hypo-onkotischer Lösungen in das Blut addierbarer, hyperpolymerer Hämoglobine zur Behandlung eines Lungenödems |
CA2600927C (en) | 2005-03-07 | 2017-04-18 | Sangart, Inc. | Compositions and methods for delivering carbon monoxide (co) and nitric oxide (no) to tissue using heme proteins as carriers |
NO2440239T3 (es) * | 2009-06-09 | 2018-02-10 | ||
US20150094267A1 (en) * | 2012-04-03 | 2015-04-02 | Kim D. Vandegriff | Succinimide-activated nitroxyl compounds and methods for the use thereof for nitroxylation of proteins |
-
2014
- 2014-03-17 JP JP2016503422A patent/JP6657070B2/ja active Active
- 2014-03-17 CA CA2906878A patent/CA2906878C/en active Active
- 2014-03-17 BR BR112015023233A patent/BR112015023233A8/pt not_active Application Discontinuation
- 2014-03-17 EP EP14765388.5A patent/EP2968597B1/en active Active
- 2014-03-17 MX MX2015013263A patent/MX2015013263A/es active IP Right Grant
- 2014-03-17 WO PCT/US2014/030569 patent/WO2014145755A1/en active Application Filing
- 2014-03-17 KR KR1020157027637A patent/KR102238718B1/ko active IP Right Grant
- 2014-03-17 CN CN201480015028.0A patent/CN105188761B/zh active Active
- 2014-03-17 AU AU2014232540A patent/AU2014232540B2/en active Active
- 2014-03-17 US US14/777,261 patent/US10821158B2/en active Active
-
2016
- 2016-06-21 HK HK16107143.3A patent/HK1219053A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
BR112015023233A2 (pt) | 2017-07-18 |
EP2968597A4 (en) | 2016-11-02 |
CN105188761B (zh) | 2020-05-15 |
BR112015023233A8 (pt) | 2019-12-03 |
CN105188761A (zh) | 2015-12-23 |
US10821158B2 (en) | 2020-11-03 |
CA2906878C (en) | 2021-09-21 |
JP6657070B2 (ja) | 2020-03-04 |
HK1219053A1 (zh) | 2017-03-24 |
KR102238718B1 (ko) | 2021-04-12 |
US20160022783A1 (en) | 2016-01-28 |
CA2906878A1 (en) | 2014-09-18 |
KR20150132235A (ko) | 2015-11-25 |
AU2014232540A1 (en) | 2015-10-29 |
AU2014232540B2 (en) | 2018-09-20 |
EP2968597A1 (en) | 2016-01-20 |
WO2014145755A1 (en) | 2014-09-18 |
EP2968597B1 (en) | 2021-08-18 |
JP2016521258A (ja) | 2016-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX371187B (es) | Péptidos terapéuticos. | |
MX2015013263A (es) | Conjugados de hemoglobina oxido de polialquileno valerato. | |
PH12014501924A1 (en) | Xten conjugate compositions and methods of making same | |
MX2019010441A (es) | Composiciones y metodos. | |
EA201401254A1 (ru) | Самостабилизирующиеся линкерные конъюгаты | |
EA201992456A3 (ru) | Самостабилизирующиеся линкерные конъюгаты | |
PH12015501753A1 (en) | Enhanced stability of novel liquid compositions | |
NZ733055A (en) | Anti-c10orf54 antibodies and uses thereof | |
MX2016008448A (es) | Conjugados de var2csa-farmaco. | |
EA201690280A1 (ru) | Композиции и способы, относящиеся к выделенным эндофитам | |
WO2014197849A3 (en) | Anti-c10orf54 antibodies and uses thereof | |
EP3082797A4 (en) | Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof | |
EA201690780A1 (ru) | Пегилированные лекарственные средства-линкеры для улучшенной фармакокинетики конъюгатов лиганд-лекарственное средство | |
MX2016002494A (es) | Composiciones que comprenden poliaminas alcoxiladas que tienen puntos de fusion bajos. | |
EA201291117A1 (ru) | Иммуногенные композиции и способы лечения неоплазии | |
IN2015DN02577A (es) | ||
TR201910866T4 (tr) | Kanser tedavisi için birleşik preparasyonlar. | |
MA40460A (fr) | Ciblage lysosomial et utilisation correspondante | |
PH12019500677A1 (en) | Cmet monoclonal binding agents, drug conjugates thereof and uses thereof | |
WO2014147503A3 (en) | Anti-bag3 antibodies for therapeutic use | |
IN2014CH00386A (es) | ||
MX2015012905A (es) | Formulaciones de factor viii recombinantes. | |
WO2014044793A3 (en) | Cd22-binding peptides | |
WO2014172309A3 (en) | Therapeutic compositions for neutralizing type i interferons, and methods of use | |
MX349487B (es) | Composiciones de higiene bucal. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |